TITLE:
Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II

CONDITION:
Pulmonary Hypertension

INTERVENTION:
bosentan

SUMMARY:

      The present trial investigates a possible use of oral bosentan, which is currently approved
      for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to
      patients suffering from PAH Class II.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 12 Years to N/A
Criteria:

        Inclusion Criteria:

          -  PAH NYHA Class II

          -  Significant elevation of mean pulmonary arterial pressure

          -  Significant elevation of pulmonary vascular resistance at rest

          -  Limited 6-minute walk distance

        Exclusion Criteria:

          -  PAH secondary to portal hypertension, complex congenital heart disease or reverse
             shunt

          -  Restrictive or obstructive lung disease

          -  Significant vasoreactivity

          -  Treatments for PAH (within 4 weeks of randomization)
      
